Drugs / DEFOSLIMOD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01800812 | Mar 2007 → Jan 2008 | cancer | Centre Hospitalier Universitaire Dijon | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DEFOSLIMOD | ChEMBL registry synonym — accepted as the source's own label CHEMBL374223 ↗ |
| Known as | OM-174 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01800812 ↗ |
| Modality | Other / unclassified | “OM-174 is an analogue of lipid A with dual action on Toll-like receptors 2 and 4.” PMID 23547558 ↗ Apr 2013 |
| Route | Intravenous | “OM-174 administered as intravenous infusion” PMID 23547558 ↗ Apr 2013 |